BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23551582)

  • 1. ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer.
    Neat MJ; Foot NJ; Hicks A; Breen R; Wilkins B; McLean E; Santis G
    Cytopathology; 2013 Dec; 24(6):356-64. PubMed ID: 23551582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration.
    Lee K; Um SW; Jeong BH; Yang JW; Choi YL; Han J; Kim H; Kwon OJ
    Intern Med; 2016; 55(21):3105-3111. PubMed ID: 27803402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.
    Bravaccini S; Tumedei MM; Ulivi P; Zoli W; Calistri D; Candoli P; Amadori D; Puccetti M
    Cytopathology; 2016 Apr; 27(2):103-7. PubMed ID: 25757141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma.
    Jurado J; Saqi A; Maxfield R; Newmark A; Lavelle M; Bacchetta M; Gorenstein L; Dovidio F; Ginsburg ME; Sonett J; Bulman W
    Ann Thorac Surg; 2013 Oct; 96(4):1196-1202. PubMed ID: 23972930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
    Yarmus L; Akulian J; Gilbert C; Feller-Kopman D; Lee HJ; Zarogoulidis P; Lechtzin N; Ali SZ; Sathiyamoorthy V
    Ann Am Thorac Soc; 2013 Dec; 10(6):636-43. PubMed ID: 24079724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration.
    Casadio C; Guarize J; Donghi S; Di Tonno C; Fumagalli C; Vacirca D; Dell'Orto P; De Marinis F; Spaggiari L; Viale G; Barberis M
    Am J Clin Pathol; 2015 Oct; 144(4):629-34. PubMed ID: 26386084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequacy of EBUS-TBNA specimen for mutation analysis of lung cancer.
    Cicek T; Ozturk A; Yılmaz A; Aktas Z; Demirag F; Akyurek N
    Clin Respir J; 2019 Feb; 13(2):92-97. PubMed ID: 30582673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
    Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
    Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
    Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
    PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
    Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
    PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.